4896.T
K Pharma,Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 799.00
+0.88%Income statement
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | — | — | 836.3M | 1.0B |
| Cost of Revenue | — | — | — | 90.0M |
| Gross Profit | — | — | — | 910.0M |
| Operating Expenses | ||||
| R&D Expense | — | — | — | — |
| SG&A Expense | 954.7M | 916.1M | 836.3M | 543.9M |
| General & Admin Expense | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — |
| Other Expenses | — | — | — | — |
| Total Operating Expenses | 954.7M | 916.1M | 836.3M | 543.9M |
| Cost and Expenses | — | — | 1.7B | 634.0M |
| Operating Income (EBIT) | (955.0M) | (916.0M) | (836.0M) | 366.0M |
| Non-Operating | ||||
| Interest Income | 4.1M | 3.0M | 265.0K | 16.0K |
| Interest Expense | 8.0K | 986.0K | — | — |
| Net Interest Income | 4.1M | 2.0M | — | — |
| Other Non-Op Income/Expense | (10.1M) | (4.5M) | 103.0K | (21.9M) |
| Non-Operating Income (excl Interest) | (93.0K) | 15.0K | 996.0K | 50.0K |
| EBT (Pre-Tax Income) | (1.0B) | (990.5M) | (844.1M) | 301.1M |
| Income Tax Expense | 2.9M | 2.7M | 2.4M | 40.7M |
| Bottom Line | ||||
| Net Income | (1.0B) | (993.0M) | (846.0M) | 260.0M |
| Earnings from Cont. Ops | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — |
| Bottom Line Net Income | (1.0B) | (993.0M) | (846.0M) | 260.0M |
| Per Share | ||||
| Basic EPS | (¥90) | (¥86) | (¥73) | ¥25 |
| Diluted EPS | (¥90) | — | — | ¥23 |
| Revenue Per Share | — | — | ¥72 | ¥98 |
| Shares | ||||
| Basic Shares Outstanding | 11.6M | 11.6M | 11.6M | 10.2M |
| Diluted Shares Outstanding | — | — | — | — |
| Profitability Metrics | ||||
| EBITDA | — | — | — | — |
| D&A | — | — | — | — |
| EBIT | (955.0M) | (916.0M) | (836.0M) | 366.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026